<DOC>
	<DOCNO>NCT00205764</DOCNO>
	<brief_summary>This international , multicenter , prospective , open , double randomise controlled phase III study compare therapeutic efficacy tandem high dose Melphalan versus triple intermediate dose Melpahaln newly-diagnosed myeloma patient</brief_summary>
	<brief_title>Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan Stem Cell Transplantation Induction Phase Prednisolone/IFN Versus IFN Maintenance Therapy</brief_title>
	<detailed_description>Patients enrol protocol start Induction therapy consist 3 cycle VAD 4 week interval follow 1 cycle IEV stem cell harvest perform . After stem cell harvest complete Patients randomise one high dose therapy arm response evaluation ( Complete remission , Partial remission stable disease ) . One group receive 2 Cycles Melphalan 200mg/m² follow stem cell transplantation , group receive 3 Cycles Melphalan 100mg/m² also follow stem cell transplantation time . After complete high dose therapy patient randomise Maintenance respond CR , PR SD . The maintenance therapy continue relapse progression disease define response criterion .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Patients newly diagnose multiple myeloma either IgG , IgG , IgD , IgE , IgM ( exclude Waldenstöm´s macroglobulinemia ) lambda kappa light chain , lowsecretory , nonsecretory disease plasma cell leukemia Performance status 0 , 1 , 2 , 3 Patients pretreated cytostatic drug Patients clearly require treatment ( usually Durie Salmon stage II III ) Patients stage I symptomatic and/or show progression disease Patients must anticipate life expectancy least 3 month Patients must adequate organ function Patients must minimum recovery period 2 week follow major surgical procedure entry study Patients must 19 70 year age , also understood patient 65 eligible poor performance status multimorbidity Women childbearing potential must negative pregnancy test must take adequate precaution prevent pregnancy treatment Patients must sign informed consent Patients 3 irradiation field Patients present initially one follow condition : Extramedullary plasmacytoma solitary plasmacytoma Monoclonal gammopathy undetermined significance Smouldering myeloma Patients irreversible performance status 4 Medical psychiatric condition compromise patient´s ability give inform consent complete study Patients congestive heart failure , NYHA III , IV Known HIV positivity Known intolerance study drug component Acute infection require systemic antibiotic study entry fully resolve Patients underlie medical condition adequately control Patients second primary malignancy ( exception cervical carcinoma situ nonmelanoma skin malignancy ) eligible unless patient diseasefree least five year</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>first line tretment</keyword>
	<keyword>high dose chemotherapy</keyword>
	<keyword>stem cell transplantation</keyword>
	<keyword>maintenance therapy</keyword>
</DOC>